using the urinary microbiome to predict bcg therapy responses in bladder cancer patients.
Published 5 years ago • 2.3K plays • Length 4:13Download video MP4
Download video MP3
Similar videos
-
1:21
how can we improve responses to immunotherapy in patients with bladder cancer?
-
4:19
novel biomarkers for outcomes identified in bcg-treated t1hg bladder cancer
-
1:55
durvalumab monotherapy for patients with bcg-unresponsive carcinoma-in-situ bladder cancer
-
2:43
genomic insights and biomarkers for treatment selection in bladder cancer
-
1:54
the correlation between composition of the gut microbiota with anti-pd-1 efficacy in cancer patients
-
0:49
how can ai and machine learning influence treatment decisions in bladder cancer?
-
1:48
dr. ramos on the role of bcg in non-muscle invasive bladder cancer
-
3:55
microbiomes and genomics: the effect on immunotherapy - bladder cancer video library
-
28:32
bcg treatment for high grade, non-muscle invasive bladder cancer
-
52:27
optimizing bladder cancer treatment during the bcg shortage era
-
0:57
using gut microbiota to enhance immunotherapy for breast cancer
-
7:32
the promise of immunotherapy in bladder cancer
-
2:31
gut microbiome signatures correlate with os in pts receiving eribulin /- pembro for hr mbc
-
0:52
managing side effects in treatment of bladder cancer
-
10:43
uropatient 19: bcg treatment for bladder cancer
-
10:19
what is bcg immunotherapy?
-
9:12
immunotherapy for nmibc: emerging and expanding indications
-
4:24
case 4: multiple lines of therapy in recurrent bladder cancer
-
34:06
the optimization of intravesical chemotherapy for superficial bladder cancer